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Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease afflicting about one third of the world’s
population and 30 % of the US population. It is induced by consumption of high-lipid diets and is characterized by liver
inflammation and subsequent liver pathology. Obesity and consumption of a high-fat diet are known to increase the risk
of Alzheimer’s disease (AD). Here, we investigated NAFLD-induced liver inflammation in the pathogenesis of AD.
Methods: WT and APP-Tg mice were fed with a standard diet (SD) or a high-fat diet (HFD) for 2, 5 months, or 1 year to
induce NAFLD. Another set of APP-Tg mice were removed from HFD after 2 months and put back on SD for 3 months.
Results: During acute phase NAFLD, WT and APP-Tg mice developed significant liver inflammation and pathology that
coincided with increased numbers of activated microglial cells in the brain, increased inflammatory cytokine profile, and
increased expression of toll-like receptors. Chronic NAFLD induced advanced pathological signs of AD in both WT and
APP-Tg mice, and also induced neuronal apoptosis. We observed decreased brain expression of low-density lipoprotein
receptor-related protein-1 (LRP-1) which is involved in β-amyloid clearance, in both WT and APP-Tg mice after ongoing
administration of the HFD. LRP-1 expression correlated with advanced signs of AD over the course of chronic NAFLD.
Removal of mice from HFD during acute NAFLD reversed liver pathology, decreased signs of activated microglial cells
and neuro-inflammation, and decreased β-amyloid plaque load.
Conclusions: Our findings indicate that chronic inflammation induced outside the brain is sufficient to induce
neurodegeneration in the absence of genetic predisposition.
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Background
Alzheimer’s disease (AD) is a progressive neurodegenera-
tive disease associated with decline in cognitive function,
impairment in memory, language and visual-spatial coord-
ination, eventually resulting in complete loss of basic
function [1]. Dementia of all forms affects about 5 % of
the population older than 65. There are approximately 5.5
million cases of AD in the USA alone, and this number is
estimated to nearly triple by the year 2040. Moreover, as
the world population lives longer, AD and dementia are
predicted to constitute a major global health problem in
the aging population of the world [2].
Major pathological hallmarks of AD present as senile
amyloid plaques that are composed of β-amyloid (Aβ)
protein and intracellular neurofibrillary tangles with
characteristic reactive microgliosis and astrogliosis. AD
is characterized by dystrophic neuritis, neuronal loss,
synaptic dysfunction, and cerebral atrophy [1]. AD can
be largely divided into early and late onset forms. Early
onset AD is induced in patients carrying genetic muta-
tions in amyloid precursor protein (APP) and/or prese-
nilin (PS1 or PS2) which induces formation of insoluble
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Aβ. Previous work showed that mice expressing mutated
APP display alterations in exploratory activity as well as ele-
vation of β-amyloid production reminiscent of AD [3, 4].
Late onset AD, also known as sporadic AD, is believed to
be induced by aberrant processing of Aβ resulting in patho-
logical lesions. In general, APP is cleaved by α-secretase
which generates soluble Aβ which has neuroprotective
functions [5]. However, when APP is cleaved by β-
secretase-1 (BACE1), it produces Aβ1–42 which is insoluble
and forms amyloid plaques that are pro-apoptotic and
neurodegenerative and are believed to induce cognitive
impairment [6, 7]. While the underlying cause of AD is not
known, advancing age, environmental stressors, and genetic
factors appear to be important precursors [8, 9]. In
addition to Aβ deposits, AD is characterized by
neurofibrillary tangles which are neuronal deposits of
hyperphosphorylated-Tau, also referred to as tauopa-
thies, which are well correlated with cognitive impair-
ment and advanced neurodegeneration [1, 10]. Due to
this association, it is still debated whether the initiat-
ing factor of AD is Aβ plaques or tauopathy [11].
In the USA, diets high in fats/lipids, which are com-
monly known as “fast foods,” are prevalent in a signifi-
cant portion of the population and are becoming an
important public health issue. High-fat diets are impli-
cated in various metabolic syndromes leading to obesity,
atherosclerosis, insulin resistance, dementia, cognitive
decline, and potentially, AD [12–16]. HFD also induces
a liver pathology called non-alcoholic fatty liver disease
(NAFLD) which is characterized by fatty liver, accumula-
tion of lipids in hepatocytes, infiltration of inflammatory
immune cells in the liver parenchyma, and secretion of
pro-inflammatory cytokines resulting in liver damage
[13, 14, 17, 18]. NAFLD is the fourth leading cause of
liver disease in the Western hemisphere. It afflicts about
30 % of the US population and is the 12th leading cause
of death in the USA among adults 45–54 years [19]. The
increase in NAFLD has been linked to increased preva-
lence of obesity and metabolic diseases in the USA and
worldwide [7]. NAFLD is associated with marked pro-
gressive inflammation, fat deposition, and fibrosis of the
liver [8, 10]. Also, a clear association exists between car-
diovascular risk factors or carotid atherosclerosis and
dementia progression leading to AD [20].
Cholesterol is an important building block of the
brain [21], which produces over 20 % of total choles-
terol in the body. This high-cholesterol content is
needed for neuronal function, as the brain cannot
access plasma cholesterol due to restrictions posed by
the blood brain barrier [22]. For this reason, neuronal
cells express high levels of cholesterol-uptake receptors
such as low-density lipoprotein receptor (LDLR), low-
density lipoprotein receptor-related protein 1 (LRP1),
and apoliprotein-E (ApoE). Up to 70 % of the brain’s
cholesterol make up the myelin sheath of oligodendro-
cytes and the membrane of astrocytes, with the remain-
der contributing to neuronal function including the
myelin sheath of neurons that relay synaptic signals.
ApoE and LRP1 are related to cholesterol metabolism
and are important risk factors contributing to the
prevalence of AD [23–25]. The ApoE variant, ApoE4,
increases AD risk and accelerates AD onset (Bu, 2009;
Liu et al., 2013). Multivariate analysis of metabolites in
the blood of AD patients showed that of the ten metab-
olites that distinguished AD from its age-matched co-
horts, six were long-chain cholesteryl esters that were
reduced in AD [26]. Also, several large cohort studies
showed that long-term treatment with statins, which
lowers serum cholesterol levels, could alleviate AD
symptoms, suggesting that alteration in lipid metabol-
ism contributes to AD pathogenesis [27, 28]. LRP1 is
an endocytic receptor highly expressed in the liver, on
neurons, and on vascular smooth muscle and glial cells
in the CNS vasculature and functions in the clearance
of Aβ from the CNS [29]. Aβ clearance is impaired in
neurons from LRP1-deficient mice [30]. Binding of
APP to LRP1 results in increased trafficking and clear-
ance of APP. However, LRP1 is also involved in Aβ pro-
duction [31]. Hence, its involvement in Aβ synthesis
and clearance makes it a prime target in AD pathogen-
esis. Deletion of LRP1 exacerbated Aβ deposition and
increased CAA [29]. It is speculated that ApoE may in-
hibit or facilitate LRP1 endocytosis of Aβ. Since ApoE4
is linked to both sporadic and familial AD and ApoE
functions in the cellular transfer of lipids through LRP1
on the cell surface, it is presumed that LRP1, ApoE, or
both are involved in dysfunction of the lipid transport
mechanism and Aβ clearance.
The increase in obesity and NAFLD prevalence in our
society, both induced by diets high in fats/lipids and their
link to chronic inflammation and metabolic diseases, mir-
rors increase in AD and AD-like syndromes. We therefore
decided to investigate the impact of NAFLD in AD patho-
genesis in an AD transgenic mouse model (APP-Tg) and
in C57BL/6, wild-type (WT) mice.
To elucidate the effect of a diet with increased lipids on
AD pathogenicity, we fed WT and APP-Tg mice with a
high-fat diet (HFD) or standard diet (SD) for 2, 5 months,
or 1 year. HFD induced systemic and CNS inflammation
that accelerated Aβ plaque deposition during acute
NAFLD (2 and 5 months) in APP-Tg mice. In WT mice,
acute NAFLD induced neuro-inflammation but did not
induce Aβ plaques. Removal of HFD after 2 months
decreased Aβ plaque load in APP-Tg mice and reversed
signs of systemic and CNS inflammation in both WT and
APP-Tg mice. WT and APP-Tg mice were kept on HFD
for up to 1 year to determine the impact of chronic
NAFLD in AD induction in WT mice and AD progression
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in APP-Tg mice. We observed advanced signs of AD, in-
cluding accelerated cerebral amyloid angiopathy (CAA),
increased tauopathy, and increased neuronal loss in APP-
Tg mice. More importantly, long-term HFD treatment
induced plaque formation, CAA, and tauopathy in WT
mice. The advanced signs of AD were associated with a
decrease in CNS expression of LRP1 during chronic
disease. These studies indicate that HFD-induced inflam-
mation plus aging are sufficient to trigger neurodegenera-




The APP-Tg mouse [B6.Cg- Tg (APPswe, PSEN1-
dE9)85Dbo/J] was generated as previously described [32].
WT mice and their APP-Tg littermates were fed either a
standard diet (SD) (Harlan Teklad TD.7912) or a high-fat
diet (HFD) (1.0 % cholesterol, 0.5 % cholic acid, 18 % tri-
glyceride; Harlan Teklad TD.88051, “Paigen diet”) [14] be-
ginning at the age of 2 months. WT and APP-Tg mice
were fed with SD or HFD for 2, 5 months, or 1 year. An-
other set of APP-Tg mice were removed from HFD after
2 months and were put back on SD for 3 months. All ani-
mal work was done in accordance with PHS guidelines
and was approved by Cornell’s Institutional Animal Care
and Use Committee (Protocol # 2008–0092).
Tissue harvest
Deeply anesthetized mice were weighed and transcardially
perfused with ice-cold phosphate buffered saline (PBS);
then, brain, spleen, and liver were collected for analysis.
After macroscopic photo documentation, all livers were
weighed and used for leukocyte preparation, except two
30-mg tissue sections which were used for histopathology
and RNA preparation. Approximately 30 mg of liver and
one brain hemisphere were flash frozen in Tissue-Tek
O.C.T. (Sakura Finetek) and stored at −80 °C. 10-μm thick
frozen sections were affixed to Superfrost/Plus slides
(Fisher), fixed in acetone, and stored at −80 °C.
Immunohistochemistry
For immunohistochemistry staining, slides were thawed
and treated with 0.03 % H2O2 in PBS to block endogen-
ous peroxidase or fixed and permeabilized in acetone
for immunofluorescence staining, blocked with casein
(Vector Laboratories) in normal goat serum (Zymed),
and then incubated with anti-CD45, phospho-Tau,
ApoE, CD31, LRP-1, 6E10, GFAP, or NeuN primary
antibodies. For immunohistochemistry, slides were then
incubated with biotinylated goat anti-rat Ig (Jackson
ImmunoResearch) and streptavidin-HRP (Zymed) and
developed with an AEC (Red) substrate kit (Zymed),
counter-stained with hematoxylin and mounted with
Fluoromount-G. For immunofluorescence assay, slides
were instead subjected to AF488, TexRed, or AF647
conjugated secondary antibody and coverslips were
mounted with Vectastain containing DAPI (Vectorlabs).
Standard or frozen histological tissue sections were
formalin-fixed and processed for hematoxylin and eosin
(H&E) or oil red-O staining and hematoxylin counter-
staining, respectively, then examined by light micros-
copy. For the green fluorescent Thioflavine S (ThioS)
staining of plaques, frozen sections were incubated with
1 % ThioS (Sigma-Aldrich) in distilled water for 5 min,
differentiated in 70 % ethanol for 5 min, washed three
times for 5 min each with distilled water and cover-
slipped with Vectastain containing DAPI (Vectorlabs).
Images were captured using a Zeiss Axio Imager M1
microscope. For further quantification of acquired images,
Zen software (Carl Zeiss) was used to obtain intensities of
signals and counting of positive signals. A detailed explan-
ation on the method of quantification is described in each
figure legend.
TUNEL assay
For TUNEL staining, which was used for detecting cell
death, the reaction mixture supplied by Roche’s In Situ Cell
Death Detection Kit, AP (Cat. No. 11 684 809 910) was
used following the protocol provided by Roche. Briefly, 10-
μm thin sections of cryogenic brain tissue which were
previously lightly fixed in acetone for 5 min and stored at
−80 °C were thawed and fixed with 4 % paraformaldehyde
for 20 to 30 min. Then, sections were permeabilized using
0.1 % Triton X-100 (Sigma-Aldrich, 9002-93-1) in sodium
citrate (Fisher Scientific, 6132-04-3) with PBS for 2 min.
TUNEL reaction mixture supplied by Roche’s In Situ Cell
Death Detection Kit, AP was added to each section and left
over night at 4 °C. Negative controls received only label
solution and no terminal transferase enzyme, while positive
controls were pretreated with DNase I Recombinant in
50 mM Tris-HCl and 10 mM MgCl2 for 10 min at room
temperature to induce DNA strand breaks. TUNEL reac-
tion mixture was then added to all samples. After washing
with PBS, sections were fixed with 4 % paraformaldehyde
for 10 min and then washed again with PBS. Images were
captured using a Zeiss Axio Imager M1 microscope.
Quantitative PCR
Brain and liver mRNA was extracted with TRIZOL
(Invitrogen) and cDNA was synthesized using High-
Capacity cDNA Reverse Transcription Kits (Applied
Biosystems) according to the protocols provided by
the manufacturers. Quantification of expression levels
of ApoE, LRP1, TLR1, TLR2, TLR6, and of pro-
inflammatory cytokines (IL-6, TNF-Α-α, IL-17, and
IL-1β) was performed using specific primers and
KAPA SYBR FAST qPCR Kit (KAPA biosystems) and
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ran on CFX96 thermocycler (Bio-Rad). Relative mRNA
expression levels of genes were analyzed using the 2^dCT
method, normalized with GAPDH as reference gene. The
fold change plotted was relative to the respective SD con-
trols. Specificity of reaction was analyzed using melting
curve analysis. Primer sequences can be viewed in supple-
mental Table 1.
ELISA assay
Splenocytes were harvested from SD or HFD-fed mice
after 1 year and treated with either PBS or ConA for
48–72 h. Supernatant was collected and used for ELISA
analysis using the eBioscience Ready Set Go Kit. Briefly,
plates were coated overnight at 4 °C with capture anti-
bodies against IL-6, TNF-α, or IL-17 and then washed.
Wells were incubated with standards and samples,
washed, and then subsequently incubated with biotin
conjugated detection antibodies. Plate was washed and
developed with 1× TMB substrate solution (eBioscience)
and the optical density (OD) was read at 450 nm using a
Biotek fluorometer (Biotek). OD values were converted
into absolute concentration using the standard curve.
Detailed quantification method of immunofluorescence
images
For immunofluorescence images, different methods were
used for its quantitative analysis. For plaque quantification,
either sizes or numbers of Thioflavin S+ plaques from
different areas of cortex of animals of different groups were
measured (area size: 6 × 105 μm2/field, ten fields/section,
blindly chosen, five animals/group). Only plaques larger
than 2 × 103 μm2 were measured and smaller plaques were
not considered. For cortical thickness quantification,
lengths of layer I to VI of cortex were measured from
blindly chosen ten different regions of whole cortex from
animals of different groups were measured for analysis
(two animals/group, blindly chosen). For analysis of frag-
mented vessels, CD31 (vascular marker)-positive cells that
lost normal brain vascular integrity (linear and smooth out-
lining of vessel) were considered as fragmented vessels, and
the numbers were counted from cortex of animals of differ-
ent groups (area size: 6 × 105 μm2/field, ten fields/section,
blindly chosen, two animals/group). All analyses (measure-
ment of length, area size) were performed using automatic
calibration function of Zen software (Carl Zeiss).
Western blotting
Brains from WT or APP-Tg mice fed with SD or HFD were
homogenized and lysed with lysis buffer containing protease
inhibitor cocktail. Samples were loaded onto a 10 % SDS
acrylamide gel and separated for 1 h and transferred to a
nitrocellulose paper. The membrane was blocked with 1 %
BSA/TBST and incubated with anti-phospho-Tau antibody
(S396 from abcam, AT8 from Millipore) or anti-Tau
antibody (Cell signaling) overnight at 4 °C and washed three
times with TBST. For loading control, anti-GAPDH (Cell
signaling) was used. Subsequently, the blot was incubated
with HRP conjugated secondary antibody for an hour at
room temperature and washed three times with TBST. The
blot was developed with Super Signal West Pico ECL solu-
tion (Thermo scientific) and exposed to X-ray film. The film
was scanned, and the intensity of each band was analyzed
with Image J software.
Statistical analyses
Data were analyzed by one-way or two-way ANOVA,
followed by Bonferroni’s multiple comparison test or
Student’d t test (two-tailed, unpaired) using GraphPad
Prism 5 software (GraphPad, La Jolla, CA). Plotted data
shown represents Mean ± SEM where significance is
indicated by *p < 0.05, **p < 0.01, ***p < 0.001.
Results
Acute stage NAFLD accelerated β-amyloid plaque
formation in APP-Tg mice but not in WT mice
It is becoming more and more evident that diets high in
fats/lipids can cause metabolic diseases such as NAFLD.
Metabolic diseases are emerging as significant contributors
to dementia and cognitive decline [33, 34]. To investigate
the impact of acute NAFLD in AD pathogenesis, we
induced NAFLD in age- and gender-matched WT and
APP-Tg mice by feeding them a high-fat diet (consisting of
1 % cholesterol and 18 % triglycerides) (Table 1) beginning
at 2 months of age. Mice were fed HFD for 2, 5 months, or
fed HFD for 2 months and put back on standard diet (SD)
for 3 months. Control mice (WT and APP-Tg mice) were
fed SD for either 2 or 5 months. To determine whether
HFD increased β-amyloid (Aβ) plaque burden in APP-Tg
mice, or induced Aβ plaques in WT mice, we analyzed
brain sections of WT and APP-Tg mice on HFD for 2 and
5 months, and of APP-Tg mice that were removed from
HFD after 2 months. We observed a significant increase in
Aβ plaque number in APP-Tg mice fed HFD at 2 and
5 months compared to SD-fed controls as visualized by
Thioflavine S-stained brain sections (Fig. 1a, b). APP-Tg
mice that were removed from HFD after 2 months had
lower plaque burden than mice that were on HFD continu-
ously for 5 months (Fig. 1a, b). Not only was the plaque
burden in APP-Tg mice fed HFD for 5 months greater, the
Table 1 Fat composition of standard diet (SD) and high-fat diet
(HFD)
Fat composition (%) SD HFD
Total fat 5.8 15.8
Cholesterol 0 1.0
Cholic acid 0 0
Triglyceride 0 18
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plaque sizes were larger in diameter compared to the aver-
age plaque size in control mice on SD and were inundated
with activated microglial cells (Fig. 1a, c). We did not ob-
serve Aβ plaques in WT mice on HFD either at 2 or
5 months (Additional file 1: Figure S1). We conclude that
HFD accelerated Aβ plaque formation in APP-Tg mice but
did not induce plaques in WT controls. Moreover, removal
of APP-Tg mice from HFD to SD lessened plaque load
compared to mice on HFD for 5 months. This suggests
that if dietary intake is corrected early in disease (prior to
signs of advanced AD), signs of AD can be reversed.
Both WT and APP-Tg mice were susceptible to
HFD-induced NAFLD steatohepatitis and systemic
inflammation
NAFLD induces severe liver inflammation and causes
significant liver damage [18]. To confirm NAFLD induc-
tion, we examined the livers of mice and observed that
both WT and APP-Tg mice on HFD exhibited significant
liver abnormality, characterized by severe hepatomegaly,
fat accumulation, and significant increase in liver size
and weight (Fig. 2a, b). Interestingly, when both WT and
APP-Tg mice were removed from HFD after 2 months
Fig. 1 HFD accelerated β amyloid plaque burden in APP-Tg mice. a Representative images of Thioflavin S (green) and Iba-1 (red) stained cortical brain
sections from age-matched APP-Tg mice. Nucleus was counter-stained with DAPI (blue). Mice were fed with SD (left top panel) or HFD (right top panel) for
2 months. A different set of mice was fed SD for five months (left middle panel) or HFD for 2 months followed by SD for 3 months (right middle panel). A
different set of mice was kept on HFD for 5 months (left bottom panel). Images on the right side are close ups of the plaque clusters seen on the images
on the left. Scale bar = 100 μm. b, c Quantification of Thioflavin S positive plaque number (b) and size (c) in cortical sections of multiple fields (ten fields/
mouse) from five mice/group in one representative experiment out of four independent experiments. * indicates p< 0.05 (One-way ANOVA with
Bonferroni post-test)
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Fig. 2 (See legend on next page.)
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and put back on normal chow for 3 months, the fatty
liver resolved and the size of their liver was similar to
control mice that were continuously on SD (Fig. 2a, b).
Notably, HFD consumption did not lead to abnormal
body weight gain in WT mice. However, in APP-Tg
mice, we observed statistically significant higher body
weight in HFD-fed mice compared to their SD controls
at 5 months (Fig. 2b). It was previously reported that
HFD treatment can increase weight gain in APP-Tg
mice [35].
NAFLD begins with accumulation of fat vesicles in the
liver cells (steatosis) which does not disturb normal func-
tions of the liver. However, further damage including oxi-
dative stress and mitochondrial abnormalities can induce
secondary inflammation and immune cell infiltration in
the liver which is known as steatohepatitis [12, 20]. To fur-
ther characterize the liver pathology in HFD-fed mice, we
performed immunohistochemistry to examine immune cell
infiltration in the liver (hepatitis), as well as oil red-O stain-
ing to evaluate fat deposition in the liver cells (steatosis)
(Fig. 2c, d). We observed multifocal hepatitis and substan-
tial steatosis in WT and APP-Tg mice fed with HFD,
whereas the livers of mice fed with SD were devoid of
hepatitis or steatosis (Fig. 2c). Although the livers of both
WT and APP-Tg mice fed with HFD showed marked lipid
droplet deposition, WT mice exhibited larger pockets of
fat deposits than APP-Tg mice (Fig. 2d, e). Analysis of
inflammatory leukocyte subpopulations revealed an
increase in CD4+, CD8+, B220+, and F4/80+ cells in the
livers of both WT and APP-Tg mice fed with HFD com-
pared to their respective SD-fed controls (Fig. 2f). We next
determined whether NAFLD induced a systemic pro-
inflammatory state in HFD mice. We performed gene
expression analysis of pro-inflammatory cytokines from
the livers of WT and App-Tg mice fed with SD or HFD
using quantitative PCR (qPCR). We observed increased ex-
pression of TNF-α, IL-6 and IL-17 in both WT and APP-
Tg mice on HFD compared to SD controls (Fig. 2g). These
findings indicate that HFD-induced NAFLD caused an
acute inflammatory state, in the absence of increased
weight gain, which accelerated plaque formation in APP-
Tg mice but not in WT mice.
HFD induced neuro-inflammation in both WT and APP-Tg
mice in acute stage AFLD
Peripheral inflammation, that is, inflammation induced
outside the CNS, has long been associated with inducing
CNS inflammation leading to neurodegeneration [12, 36].
To determine whether NAFLD-induced inflammation
(which initially starts in the liver) induces CNS inflamma-
tion in mice fed with HFD that may account for the
accelerated plaque burden in APP-Tg mice (Fig. 1), we
performed cytokine gene expression analysis on the brains
of WT and APP-Tg mice fed with either HFD or SD. We
observed higher levels of TNF-α and IL-6 mRNA in the
brains of APP-Tg mice on HFD compared to SD controls
(Fig. 3a). Interestingly, WT mice on HFD expressed higher
levels of IL-1β and IL-17 mRNA in the CNS compared to
SD controls (Fig. 3b). This indicates that peripheral
inflammation has a significant effect on induction of CNS
inflammation (Fig. 3b).
Toll-like receptors (TLRs), which are innate immune
receptors that recognize microbial components called
pathogen-associated molecular patterns (PAMPS) or en-
dogenous ligands released by necrotic or injured cells
called damage-associated molecular patterns (DAMPS),
have been recently described in CNS inflammation [37].
TLR association with specific DAMPs leads to receptor
activation, which subsequently leads to initiation of an in-
flammatory cascade such as the one observed in Fig. 3a, b.
We investigated whether TLRs were altered in the CNS of
WT or APP-Tg mice fed with HFD compared to controls
during acute NAFLD. We focused on TLRs 1, 2, and 6 as
these TLRs are known to recognize lipoproteins and
glycolipids among others [38]. We observed significant
upregulation of TLR 1, 2, and 6 in the brains of WT and
APP-Tg mice fed with HFD compared to SD controls
(Fig. 3c). This confirms that HFD induced a potent inflam-
matory cascade inducing TLRs and culminating in secre-
tion of pro-inflammatory mediators in the CNS.
Microgliosis is characterized by an increase in the num-
ber activated microglial cells accumulating around CNS le-
sions or during CNS injury and is believed to contribute to
CNS pathology in models of neuro-inflammation [39, 40].
We found that WT and APP-Tg mice fed with HFD
(See figure on previous page.)
Fig. 2 HFD induced acute liver pathology and inflammation in WT and APP-Tg and mice. a Representative images of livers from WT or APP-Tg mice
fed with HFD or SD, with corresponding liver and body weights of their respective age-matched SD-fed controls. Scale bar indicates 5 mm (b). ** and
*** indicate p < 0.01 and p < 0.001, respectively (two-way ANOVA with Bonferroni post-test). c Representative CD45+ staining of liver sections from WT
or APP-Tg mice fed with SD or HFD for 2 months. d Representative oil O-red staining on frozen tissue sections of livers from WT or APP-Tg
mice fed with SD or HFD for 2 months. e Relative positive pixel count of oil O-red staining quantified using Zen software (Carl Zeiss). * and
*** indicate p < 0.05 and p < 0.001, respectively (two-way ANOVA with Bonferroni post-test). f Quantitative analysis of total leukocyte numbers (CD45
+) isolated from the livers of 2-month SD or HFD-fed WT and APP-Tg mice by flow cytometry. ** indicates p < 0.01 (two-way ANOVA with Bonferroni
post-test, n = 3/group). g TNF-α, IL-6, and IL-17 mRNA expression in livers of WT and APP-Tg mice fed with SD or HFD for 2 months. ** indicates p <
0.01 (two-way ANOVA with Bonferroni post-test, n = 3/group, representative experiment of four independent experiments)
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showed markedly pronounced staining for the activated
microglial marker Iba-1, in areas surrounding the choroid
plexus (Fig. 3d and Additional file 2: Figure S2). Interest-
ingly, despite the absence of plaques in WT mice on HFD,
these mice showed intense Iba-1 staining and increased
microglial cell numbers, suggesting that the CNS of these
mice is being primed for a neuroinflammatory or patho-
logical event (Fig. 3d, e). Interestingly, Iba-1 staining was
significantly reduced in mice that were removed from HFD
after 2 months, indicating that HFD-induced systemic in-
flammation is the major factor contributing to CNS inflam-
mation and microglial activation (Fig. 3d, e). We also
observed Iba-1 staining in APP-Tg mice fed with SD, albeit
to a lesser extent (Fig. 3d, e), suggesting pre-existing pro-
inflammatory conditions in the CNS of these mice as
previously reported [41]. Since microglial cell activation is
higher in the choroid plexus of HFD-fed mice, we asked
whether such increased microglial activation is observed in
plaque-rich areas in the brains of APP-Tg mice fed with
HFD. Indeed, we observed higher microglial activation in
plaque-rich regions in brains from mice fed HFD for
2 months compared to those that were fed SD (Fig. 3f, g).
Increased microglial activation was also observed in cortical
and hippocampal areas devoid of β-amyloid plaques in
HFD-fed WT and APP-Tg mice compared to their SD-fed
controls (Additional file 3: Figure S3 A–D). This indicates
that HFD-induced NAFLD can trigger generalized micro-
glial activation in the brains of both WTand APP-Tg mice.
Impact of HFD on chronic disease: NAFLD caused advanced
signs of AD in both WT and APP-Tg mice 1 year later
To mimic the life-long diet pattern in humans, we kept
WT and APP-Tg mice on HFD for up to 1 year to evaluate
its impact on systemic as well as on brain inflammation
and subsequent AD pathogenesis. First, we analyzed the
accumulation of fat deposition (steatosis) in the liver after
1 year of HFD treatment in both WT and APP-Tg mice.
We observed significantly higher accumulation of fat in
both WT and APP-Tg mice fed with HFD, indicating on-
going NAFLD (Additional file 4: Figure S4). Because we
observed accelerated plaque formation in APP-Tg mice at
2 and 5 months on HFD that is comparable with the
plaque loads and sizes seen in these mice around 18–24
months on SD, we anticipated an even greater plaque bur-
den in APP-Tg mice fed with HFD for 1 year. Surprisingly,
instead of increased plaques, we observed a significant
decrease in overall plaque load in APP-Tg mice on HFD
compared to those on SD (Fig. 4a). We examined and
quantified Aβ plaque deposition in the cortex and hippo-
campus (Fig. 4a). We observed a dramatic reduction in Aβ
plaques in HFD-fed mice compared to SD-fed controls in
these regions (Fig. 4a, c). Also, close-up images of plaques
from these mice showed increased reactive astrocyte infil-
tration in SD-fed mice compared to HFD-fed mice (Fig. 4b).
Moreover, from 2 months (Fig. 4d upper panel) and up to
1 year (Fig. 4d bottom panel) of HFD treatment, we ob-
served a reduction of GFAP signal in the hippocampus
compared to control treatment (Fig. 4e). We hypothesized
that the reduced plaque load may be a result of neuronal
and/or glial cell death or due to increased plaque clearance
by astrocytes, which can exert a protective response to fi-
brillar Aβ by removing it from the CNS [42]. To determine
whether the decreased plaque load in the CNS of APP-Tg
mice was the result of neuronal death leading to a decrease
in Aβ production, we stained frozen brain sections with
antibodies to TUNEL which stains DNA in dead or dying
cells, and to NeuN which stains neurons. We observed
higher incidence of TUNEL-positive NeuN cells in HFD-
fed mice compared to SD-fed APP-Tg mice (Fig. 4f, g). Fur-
ther, quantification of neuronal cells in the cortex showed
that they were significantly decreased in APP-Tg mice fed
with HFD compared to SD controls (Fig. 4h, i). Also, the
thickness of the cortex was shrunken in APP-Tg mice fed
with HFD compared to SD controls (Fig. 4h, j). Moreover,
the intensity of NeuN-positive signal in the dentate gyrus
was reduced in APP-Tg mice fed with HFD compared to
SD-fed controls (Fig. 4h, k). Since astrocytes and neurons
are major producers of Aβ, these findings suggest that re-
duction in neuronal cells and astrocytes may be responsible
for the reduced plaque burden.
Long-term HFD-induced AD plaques and neuronal cell
loss in WT mice
WT mice developed inflammation both in the periphery
and in the CNS similar to and to some degree greater
than APP-Tg mice in acute NAFLD (Figs. 2 and 3).
(See figure on previous page.)
Fig. 3 Brains of HFD-fed mice have increased inflammation and microglial activation. mRNA expression of pro-inflammatory cytokine in brains of APP-Tg
(a) and WT mice (b). ** indicates p< 0.01 (two-tailed student t test, n= 2 performed in triplicates representative of four independent experiments). c Brain
mRNA expression of TLR1, TLR2, and TLR6 of WT or APP-Tg mice after being on SD or HFD for 2 months. *, **, *** indicate p< 0.05, p< 0.01, and p< 0.001
(two-tailed student t test, n= 2 performed in triplicates representative of four independent experiments). d Representative images of Iba-1 (red) near the
choroid plexus from WT mice and APP-Tg mice fed with SD or HFD for 2 or 5 months, or initially with HFD for 2 months and then put back on SD for
3 months. Nucleus was counter-stained with DAPI (blue). e Intensity of Iba-1 expression from d measured from different fields (n= 20, three mice/group)
using Zen Software (Carl Zeiss). ** and *** indicate where p< 0.01 and p< 0.001, respectively. (two-way ANOVA with Bonferroni post-test) f Representative
image of relative localization of Iba-1 (red) with β- amyloid plaque (green) from cortices of brains of mice fed with SD or HFD for 2 months. Nucleus was
counter-stained with DAPI (blue). Scale bar = 50 μm. g Intensity of Iba-1 signal from (f) was measured from different plaques using Zen Software (Carl Zeiss)
(n= 20, five mice/group). *** indicates p< 0.001 (two-tailed student’s t test)
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Fig. 4 Long-term HFD decreased NeuN+ cells, Aβ plaques, and astrocytes in APP-Tg mice. a Representative images of cortex (left panel) or hippocampus
(right panel) from APP-Tg mice fed with SD or HFD for 1 year, stained with anti-6E10 anti-β-amyloid antibody (green), anti-GFAP (red), and DAPI (blue).
Scale bar = 200 μm. b Representative zoomed-in images of reactive astrocyte (red) around plaque (green) from the cortex of SD or HFD-fed APP-Tg mice.
Scale bar = 50 μm. c Number of plaques from different regions of cortex (n= 10) or hippocampus (n= 10). * indicates p< 0.05 (two-tailed student’s t test,
n= 2 mice/group, representative of two independent experiments). d Representative with SD or HFD for 2 months (top panel) or 1 year
(bottom panel) stained with anti-NeuN (red), and anti-GFAP antibody (gold). Zoomed-in image was inserted as inlet. e Relative intensity of
GFAP signal from d (n = 10). ** indicates p < 0.01 (two-tailed student’s t test, twice mice/group, representative of two independent experi-
ments). Representative images (f) and quantitative analysis (g) of images from brain cortex of APP-Tg mice fed with SD or HFD stained with NeuN (red), or
TUNEL (green). TUNEL/NeuN double positive cells were counted from ten different fields and quantified as a percentage of total cell count. *** indicates p
< 0.001 (two-tailed student’s t test, two mice/group). h Representative image of brain sections from SD or HFD-fed APP-Tg mice stained with anti-NeuN
antibody (red). Dotted lines indicate the outline of NeuN-positive signal in cerebral cortex. i Quantitative analysis
of h *** indicates p < 0.001 (two-tailed student’s t test, two mice/group). j Cortical thickness of brains from SD or HFD-fed mice measured
from ten different fields. ** indicates p < 0.001 (two-tailed student’s t test, two mice/group). k Quantitative analysis of h, showing intensity
of NeuN-positive signal measured from ten different fields of dentate gyrus from mice fed SD or HFD. ** indicates p < 0.001 (two-tailed
student’s t test, two mice/group)
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Brains of WT mice had increased numbers of activated
microglial cells and high levels of pro-inflammatory media-
tors but no evidence of plaque induction during acute
NAFLD. We examined brains of WT mice to determine
whether aging (6 months later) induced Aβ plaques in the
presence of HFD. Indeed, we observed plaque formation in
the cerebral cortex of WT mice fed with HFD (Fig. 5a).
This finding is significant because it indicates that HFD-
induced chronic inflammation plus aging is sufficient to in-
duce signs of AD in mice lacking genetic predisposition to
AD (Fig. 5a). To test whether WT mice also show in-
creased neuronal apoptosis as was observed in APP-Tg
mice, we performed TUNEL/NeuN double-staining. Simi-
lar to APP-Tg mice, we observed a higher incidence of
TUNEL-positive NeuN staining (not significant) in WT
mice on HFD compared to SD (Fig. 5b, c). To test if
HFD induced neuronal loss, we quantified the number
of NeuN-positive cells in different brain regions. In-
deed, we observed a statistically significant reduction of
NeuN-positive signal in the cortex (Fig. 5d, e) and re-
duced cortical thickness (Fig. 5d, f ) in WT mice fed
with HFD compared to SD controls. Also, the intensity
of NeuN-positive signal in the dentate gyrus was re-
duced in WT mice fed with HFD compared to SD con-
trols (Fig. 5d, g). This suggests that long-term HFD
treatment in WT mice is sufficient to induce plaque
formation and neuronal loss. Interestingly, we did not
observe any decrease or reduction in astrocytes or Aβ
plaque deposition in the brains of WT mice on SD vs.
HFD as was observed in APP-Tg mice (Additional file
5: Figure S5).
Long-term HFD induced advanced signs of AD in WT and
APP-Tg mice
In addition to Aβ senile plaque deposits, aggregation of
neurofibrillary tangles composed of hyperphosphorylated-
Tau (pTau) is a prominent hallmark of advanced AD. Tau
is the microtubule-associated protein (MAP) that is
involved in the delivery of neurotransmitter signals
through microtubule tracks in axons [43, 44]. In its hyper-
phosphorylated state such as in AD, or tauopathies, Tau is
aggregated and unable to relay proper neurotransmission,
leading to neuronal dysfunction [10, 11, 45]. To test
whether tauopathy is induced in APP-Tg mice 1 year after
being on HFD, we stained the brains of mice fed with
either HFD or SD with an antibody that binds to pTau.
We observed very intense pTau staining in the hippocam-
pus and cortex of APP-Tg mice but not in SD controls,
indicating that long-term HFD induced major advanced
signs of neurodegeneration (Fig. 6a). We next determined
whether WT mice on HFD also exhibit pTau staining. In-
deed, similar to APP-Tg mice, WT mice exhibited intense
pTau staining in the dentate gyrus that was not observed
in SD-fed mice (Fig. 6a). This was further confirmed by
Western blot using pTau-specific antibodies (S396 and
AT8) showing increased ratio of pTau/Tau in both HFD-
fed WT and APP-Tg mice compared to their SD controls
(Fig. 6b, c). These findings strongly indicate that HFD in-
duced major advanced signs of neurodegeneration, not
only in animals predisposed to AD (APP-Tg mice) but was
sufficient to induce them in WT mice as they age.
We next investigated whether cerebral amyloid angiopa-
thy (CAA), a sign of advanced AD characterized by accu-
mulation of Aβ1–40 in the brain vasculature and believed
to cause micro-infarction leading to neurological dysfunc-
tion and neuronal death, was induced by HFD [46, 47]. Aβ
deposition in cerebral vessels lowers the force of Aβ
clearance, resulting in increased parenchymal Aβ build-
up. We examined brains of mice after double-staining
with antibodies to Aβ and CD31 (marker for the endothe-
lial vasculature). We observed intense and frequent signs
of CAA, evidenced by Aβ accumulation in the vessels of
WT and APP-Tg mice fed with HFD but not in SD
controls (Fig. 6d, e). Throughout the brains of WT and
APP-Tg mice, we observed what appears to be a high fre-
quency of broken or fragmented vessels (Fig. 6f). These
findings indicate that HFD can induce signs of advanced
AD in WT mice and profoundly accelerate signs of
advanced AD in APP-Tg mice fed with HFD.
HFD decreased LRP1 and increased the inflammatory
profile in the brains of WT and APP-Tg mice during
chronic NAFLD
LRP1 is highly expressed in, neurons and glial cells, as well
as in the liver and vascular smooth muscle, and functions
in the clearance and trafficking of Aβ from the CNS.
However, studies show that LRP1 is also involved in Aβ
production [31]. Thus, LRP1 involvement in Aβ synthesis
and clearance makes it a prime target in AD pathogenesis.
Deletion of LRP1 exacerbated Aβ deposition and
increased CAA (Kanekiyo et al., 2012). We investigated
whether LRP1 expression is altered in the CNS of HFD-
fed mice both at early (acute NAFLD, 2 months) and
chronic NAFLD (after 1 year on HFD) compared to SD
controls. We observed increased LRP1 expression in the
brains of APP-Tg mice fed with HFD but not in HFD WT
mice (Fig. 7a). However, in chronic NAFLD, both WT and
APP-Tg mice fed with HFD expressed significantly lower
levels of LRP1 in CNS tissue compared to SD controls
(Fig. 7a). This decrease in LRP1 expression is consistent
with the increased neurodegenerative changes observed in
chronic disease and may reflect a protective role for LRP1
in AD [31].
ApoE is a known risk factor for AD. Its variant ApoE4 in-
creases the risk of AD and accelerates AD onset (Bu, 2009;
Liu et al., 2013). ApoE is a ligand for LRP1, and its main
function is the cellular transfer of lipids through LRP1 on
the cell surface. There is mixed evidence as to whether
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ApoE is involved in binding and/or clearance of Aβ [48]. It
is speculated that ApoE may inhibit or facilitate LRP1-
mediated endocytosis of Aβ [49]. We therefore analyzed
ApoE expression in both acute and chronic NAFLD and
found no difference in ApoE expression in acute or chronic
NAFLD in WT or APP-Tg mice (Fig. 7b). This indicates
that ApoE expression/function remains relatively un-
changed despite accelerated signs of neurodegeneration
Fig. 5 Long-term HFD induced Aβ plaque formation in brains of WT mice. a Representative images of brain sections from HFD-fed WT mice stained
with anti-NeuN (red) and anti-6E10 (green). b Representative images of brain sections (cortex) from SD or HFD-fed WT mice double-stained with anti-
NeuN (red) and TUNEL (green). c TUNEL/NeuN double positive cells were counted from ten different fields and quantified as a percentage of total cell
count. d Representative image of brain sections from SD or HFD-fed WT mice stained with anti-NeuN antibody (dotted lines indicate the
outline of NeuN-positive signal in the cerebral cortex. e Quantitative analysis of d, showing numbers of NeuN+ cells from ten fields of the
brain. ** indicates p < 0.01 (two-tailed student’s t test, two mice/group). f Comparison of cortical thickness of brains from SD or HFD-fed mice. Thickness
of cortex was measured from ten different fields. ** indicates p < 0.01 (two-tailed student’s t test, two mice/group). g Quantitative analysis
of d, capturing the intensity of NeuN-positive signal measured from ten different fields of the dentate gyrus from brains of mice fed with SD or HFD.
** indicates p < 0.01 (two-tailed student’s t test, two mice/group). These are representative findings from two independent experiments
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and neuronal loss. In contrast, LRP1 expression increased
in acute/early phase of NAFLD in APP-Tg mice, but was
unchanged in WT mice on HFD. LRP1 levels decreased
significantly during chronic NAFLD in both WT and APP-
Tg mice on HFD. This leaves us to speculate that a
decrease in LRP1 expression/function is linked to advanced
signs of AD.
To determine whether systemic inflammation was
maintained through the chronic phase of NAFLD, we
examined the cytokine profiles of lymphocytes in
Fig. 6 Long-term HFD induced advanced signs of AD in WT and APP-Tg mice. a Representative images of hippocampus from WT and APP-Tg mice fed
with SD or HFD for 1 year, stained with anti-phosphorylated-Tau (S396) antibody. b, c Western blot analysis of brain homogenate of WT or APP-Tg mice
fed with SD or HFD for 1 year (b). Phosphorylated-Tau was detected with S396 or AT8 antibody and total Tau protein was detected with anti-Tau antibody.
GAPDH was used as loading control. Intensity of phospho-Tau was normalized by that of Tau protein which was further normalized by intensity of GAPDH
and depicted in graph (c). ** indicates p< 0.01. (two-tailed student’s t test, n= 2). d Representative brain sections from WT mice fed SD or HFD and stained
with anti-CD31 (red) and anti-β- amyloid antibody, 6E10 (green) to assess the degree of cerebral amyloid angiopathy (CAA) and vasculopathy. The top
three panels depict SD controls, the bottom three panels show HFD-induced CAA. e Representative brain images from APP-Tg mice double-stained
with antibodies to β-amyloid (6E10) and CD31 (vasculature) for SD (top three panels) or HFD (bottom three panels) to evaluate CAA. f Quantification
of fragmented vessels taken over multiple microscopic fields throughout the brains of WT and APP-Tg mice fed with SD or HFD. *** indicates p <
0.001 (Two-tailed student’s t test, ten fields/mouse, n = 2 mice/group)
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peripheral lymphoid organs of APP-Tg mice after
1 year on SD or HFD. We observed increased TNF-α,
IL-6, and IL-17 in APP-Tg mice fed with HFD com-
pared to SD controls (Fig. 7c). Similarly, lymphocytes
from WT mice fed with HFD secreted high levels of
the pro-inflammatory cytokines TNF-α, IL-6, and IL-
17 compared to their SD counterparts (Fig. 7c). To
determine whether this chronic HFD-induced systemic
inflammatory profile is consistent with the inflammatory
profile of the CNS, we performed quantitative RT-PCR of
these cytokines on brain samples. Indeed, we observed
that these cytokines were highly upregulated in the brains
of WT and APP-Tg mice fed with HFD compared to their
SD counterparts (Fig. 7d). Together, these results suggest
that augmented systemic immune responses induced by
HFD have a sustained impact on increased brain inflam-
matory response and profoundly impact neurodegenera-
tion (Fig. 7d).
Discussion
We demonstrate that a modest increase in dietary lipids
fed to WT or APP-Tg mice induced acute inflammation
of the liver followed by a chronic inflammatory state.
This HFD-induced acute inflammation was character-
ized by invasion of inflammatory immune cells into the
liver parenchyma and increased production of pro-
inflammatory cytokines by immune cells locally (liver)
and systemically (lymphoid organs). Concomitant with
this increased peripheral inflammatory state, we ob-
served profound acceleration in neurodegenerative signs
and increased neuro-inflammation in APP-Tg mice
compared to mice that remained on SD. We observed
acceleration in β-amyloid plaque formation leading to
higher plaque loads, larger plaque size, and increased
microgliosis, and astroglyosis in APP-Tg mice. In AD
patients’ brain, activated microglial cells have been
observed around plaques and were initially thought to
Fig. 7 Long-term HFD decreased LRP1 and maintained chronic inflammation in brains of WT and APP-Tg mice mRNA expression of LRP1 (a) or ApoE (b)
was analyzed in the brains of mice fed SD or HFD for 2 months or 1 year by quantitative real-time PCR. * and ** indicate p< 0.05 and p< 0.01, respectively
(two-tailed student’s t test, n= 2 mice/group performed in triplicates, representative of two independent experiments). c Splenocytes from mice fed SD
or HFD for 1 year were stimulated with PMA-ionomycin for 3 days, supernatants were collected and pro-inflammatory cytokines (TNF-α, IL-6, IL-17) were
quantified by ELISA. *, **, and *** indicate p< 0.05, p< 0.01, and p< 0.001, respectively (two-tailed student’s t test, n= 2 mice/group performed in triplicates,
representative of two independent experiments). d mRNA expression level of pro-inflammatory cytokines (TNF-α, IL-6, IL17) was analyzed in brain samples
from mice fed HFD or SD for 1 year by quantitative real-time PCR * and ** indicate p< 0.05 and p< 0.01, respectively (two-tailed student’s t test, n= 2
mice/group performed in triplicates, representative of two independent experiments)
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be a clearance mechanism to remove Aβ plaques from
the CNS. However, these activated microglial cells did
not reduce plaque burden [41], but induced neuronal
damage instead. In our study, APP-Tg mice on SD ex-
hibited activated microglial cell accumulation in the
brain which is consistent with a previous report of a
pro-inflammatory state in these mice [42]. Compared to
SD-fed mice, microglial cell accumulation was increased
by about fourfold in HFD-fed mice, and this correlated
with increased pro-inflammatory cytokine expression in
these mice. This increase in both CNS and peripheral in-
flammation was reversed when mice were removed from
HFD and put back on SD; we observed decreased acti-
vated microglial cell numbers, decreased liver pathology,
and decreased pro-inflammatory cytokines in the CNS.
This reversal in inflammation was consistent with re-
duced Aβ plaque burden. This indicates that induction
of NAFLD in the liver may be an important factor that
can induce the accelerated signs of AD observed in
APP-Tg mice.
Interestingly, WT mice on HFD exhibited a similar in-
crease in activated microglia accumulation even though
they did not exhibit signs of Aβ plaque deposition at 2 or
5 months on HFD. WT mice on HFD exhibited more pro-
nounced lipid deposits in liver cells than APP-Tg mice, but
they did not develop Aβ plaques in the acute phase of
NAFLD. WT mice fed with HFD showed increased pro-
inflammatory cytokine gene expression (TNF-α, Il-6 and
IL-17) in the liver and in peripheral lymphoid organs, and
liver pathology was more pronounced in WT mice, with
higher immune cell infiltration in the liver parenchyma.
Both IL-6 and Il-17 pro-inflammatory cytokines were
highly pronounced in WT mice but were almost absent in
SD controls. Il-6 and Il-17 play pathogenic roles in multiple
sclerosis [50, 51]. The profound increase in the expression
of these cytokine genes strictly coincides with increased
activated microglia in the CNS, potentially setting the stage
for the neurodegeneration we observed in WT mice on
HFD 1 year later. Moreover, when WT mice were removed
from HFD diet and placed on SD, inflammation ceased,
liver pathology was reverted, and activated microglial cells
were absent. Of interest was the absence of plaques in these
WT mice even though they showed all other signs of in-
flammation observed in the APP-Tg animals. This indicates
that HFD-induced systemic inflammation primed the CNS
for the neurodegeneration which we later observed. These
studies suggest that AD can be induced and driven by
acute-chronic systemic inflammation in individuals that are
not otherwise genetically predisposed. It also indicates that
early intervention can reverse the process.
The brains of APP-Tg mice on long-term HFD had
significantly less plaques compared to SD-fed mice.
APP-Tg mice showed a dramatic decrease in Aβ pla-
ques in the hippocampus, the olfactory bulb, and the
mid brain. Also striking was the absence of astrocytic
tracks in brain areas where Aβ plaques were absent or
diminished, such as the hippocampus and midbrain.
Moreover, we observed neuronal loss and increased
apoptotic neurons in hippocampus and mid brain. This
was not the case for older mice (15–24 months) on SD,
indicating that aging alone is not responsible for the
loss of astrocytes. As discussed above, removal from
HFD reduced plaque load and decreased inflammatory
signals. Thus, astrocytic loss may be a result of acceler-
ated AD pathology resulting in CNS toxicity. Astrocyte
death can lead to neuronal death because of the critical
role they play in neuronal function [42]. Increased
neuronal death may also explain the decreased plaque
load in chronic AD due to decreased APP production.
Based on these studies, we conclude that chronic
inflammation induced outside the CNS (in the liver) is
sufficient to induce AD-like symptoms in the absence
of predisposing genetic factors.
Signs of CAA and hyperphosphorylated-Tau (pTau)
expression are representative of advanced AD. pTau ag-
gregates and is unable to signal proper neurotransmis-
sion, leading to neuronal dysfunction; and CAA results
in a lack of Aβ clearance from the CNS. We observed
strong expression of pTau and evidence of CAA in both
WT and APP-Tg mice on HFD but not in SD controls.
pTau was increased in HFD-fed WT and APP-Tg mice
compared to SD controls, even though Aβ was induced
much later in WT mice. Thus, if CAA and tauopathy
represents advanced AD, one may argue that AD accel-
erated more dramatically in WT mice than APP-Tg
mice, and it may be regulated differently in genetically
predisposed (APP-Tg) vs. non-predisposed individuals
(WT). CAA involves deposition of amyloid in cerebral
vasculature and is a hallmark of advanced AD resulting
in pathological changes in cerebral blood vessels referred
to as vasculopathies. Signs of CAA were more extensive
in APP-Tg mice compared to WT mice on HFD. These
findings clearly indicate that HFD-induced inflammation
can result in significant CNS destruction and pathology
over a lifetime.
Low-density lipoprotein receptor-1 (LRP1) is involved
in a number of pathways linked to AD pathogenesis and
has multiple functions. It is most highly expressed in
brain, liver, and lungs. In the brain, it is highly expressed
in glial cells, neurons, and cells of the cerebral vascula-
ture. LRP1 can directly regulate gene expression through
its intracellular domain and can regulate the endocytosis
of many diverse ligands including ApoE, APP, and Aβ.
LRP1 appears to have bimodal opposing functions linked
to AD pathogenesis. It is involved in Aβ clearance and
Aβ production. It mediates Aβ clearance by cellular up-
take followed by lysosomal degradation and/or transcy-
tosis of intact Aβ across the BBB to the circulation and
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consequent peripheral clearance [49]. We observed in-
creased LRP1 expression in APP-Tg mice on HFD, but not
in WT mice, during the acute phase of NAFLD. Increased
LRP1 expression may represent its increased function in
clearance of Aβ from the CNS in APP-Tg mice during ac-
celerated Aβ production. It is possible that LRP1 did not
increase in WT mice on HFD due to the absence of Aβ in
the CNS of these mice during acute NAFLD. However,
during chronic NAFLD, we observed a significant decrease
in LRP1 in the CNS of both WT and APP-Tg mice on
HFD. This decrease coincides with advanced signs of AD,
including reduced Aβ plaque load, reduced number of
neurons and astrocytes, and increased vascular destruction,
suggesting that LRP1 plays a protective role in AD. It is
possible that the reduction in LRP1 expression during
chronic NAFLD may be a result of glial and neuronal cell
loss, as these cells abundantly express LRP1. Alternatively,
advanced AD may have rendered LRP1 defective in clear-
ing Aβ from the CNS.
It is interesting that no change in ApoE expression
was observed during acute or chronic stages of NAFLD,
despite significant neuronal and glial cell loss. The major
function of ApoE is to transport cholesterol and other
lipids in plasma and brain through a variety of cell sur-
face receptors including LRP1 [49]. Astrocytes are the
main source of ApoE [25, 52]. Since cholesterol is a crit-
ical component of glial and neuronal cell membrane in-
cluding the myelin sheath, it is possible that a reduction
of GFAP+ astrocytes resulted in limited cholesterol pro-
duction needed for membrane synthesis and CNS repair.
However, this is unlikely since such a reduction may
have resulted in decreased ApoE. Other likely scenarios
for no change in ApoE include its function in cholesterol
trafficking was unhindered, whereas its function in Aβ
trafficking was defective, or that the reduced plaque bur-
den in chronic NAFLD was the result of increased Aβ
trafficking by ApoE. The involvement of Aβ, LRP1, and
ApoE in neurodegeneration and AD pathogenesis is
quite complex and needs further investigation beyond
these studies.
Our studies address a growing problem in our society
that relates to metabolic syndromes due to diets high in
fat/lipid consumption and their impact on neurodegenera-
tion. NAFLD is prevalent in as much as a third of the
world’s population. Similarly, AD frequency is rapidly
growing. We showed that a modest increase in dietary lipid
content caused increased systemic inflammation followed
by increased neuro-inflammation and accelerated AD signs
in APP-Tg mice. More importantly, we showed that WT
mice become susceptible to developing Aβ plaques after
long-term HFD intake and developed advanced cellular
signs of AD. Moreover, APP-Tg mice on HFD exhibit se-
vere CNS damage stemming from the effects of chronic
HFD. These findings highlight a growing problem in our
society whereby consumption of foods high in lipids over a
lifetime can have detrimental consequences such as accel-
erating signs of AD in potentially susceptible individuals or
inducing them in those that are not susceptible. An im-
portant and critical finding of these studies is that change
from HFD to SD, before irreversible CNS damage sets in,
completely reverses signs of AD. This suggests that life
style changes such as reducing one’s lipid/fat intake can
have a profound impact on disease outcome. Recent stud-
ies from others showed that a high-cholesterol diet (5 %)
fed to mice can induce advanced pathological signs of AD
[53–55]. Similar to our findings, these studies showed that
diets high in cholesterol increased hyperphosphorylated-
Tau deposition, and decreased cognitive function in both
WT and AD models [53–55]. Also, one of the studies
showed increased ventricular volume which is reminiscent
of the decreased cortical thickness and increased neuronal
apoptosis we observed in HFD-fed WT and APP-Tg mice
[55]. These findings are in line with ours and highlight a
critical role for a diet high in fats and lipids in inducing
pathological outcomes. However, our model differs in the
cholesterol content. We fed mice a diet containing 1 %
cholesterol plus 18 % triglyceride which consistently
induces NAFLD that is characterized by acute inflamma-
tion and significant liver damage in mice.
Conclusions
In summary, chronic high-fat diet induced NAFLD, and its
secondary neuro-inflammation is sufficient to cause neuro-
degeneration in both WTand APP-tg mice. We believe this
study stands to benefit millions of people who are in danger
of developing AD or people currently suffering from early
signs of AD or dementia. Future studies hinge on elucidat-
ing the fine changes conferred upon neuronal function
resulting in their loss or dysfunction, correlating with
behavioral and cognitive defects, and defining cerebral
vasculopathies resulting from these events.
Additional files
Additional file 1: Table S1. Sequences of primers used for quantitative
PCR analysis.
Additional file 2: Figure S1. Brain sections from SD and HFD-fed
WT mice at 2 months stained with Thioflavin S (Green). Sections were
counter-stained with DAPI to visualize nuclei. Scale bar = 200 μm.
Additional file 3: Figure S2. Zoomed-in images of Iba-1 (red) staining
of respective time points from Figure 2d. Nucleus was counter-stained
with DAPI (blue).
Additional file 4: Figure S3. Iba-1 (red) staining of cortical (A) and
hippocampal (C) areas of brains devoid of plaques from WT and APP-Tg
mice fed with SD or HFD for 2 months. Iba-1+cells were counted from
different fields of the cortex (n = 20 from two animals) and hippocampus
(n = 10 from two animals). ** and *** indicate p < 0.01 and p < 0.001,
respectively. (two-way ANOVA with Bonferroni post-test).
Additional file 5: Figure S4. Positive pixel count of oil O-red staining
in the liver of WT and APP-Tg mice fed with SD or HFD for 1 year. Fixed
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liver sections were stained with oil O-red and positive pixels (red) were
counted using Zen Software. **indicates p < 0.01. (two-way ANOVA with
Bonferroni post-test, n = 2).
Additional file 6: Figure S5. Representative images of hippocampal
sections from WT mice fed with SD or HFD for 1 year and stained with
anti-NeuN (pink), GFAP (gold). Scale bar = 200 μm.
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